{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T14:35:17Z","timestamp":1793284517986,"version":"4.5.0"},"reference-count":46,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","license":[{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Kidney360"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:sec>\n                    <jats:title>Key Points<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>Both patients and clinicians were broadly supportive of combination therapy in CKD.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Implementation remains the main challenge, especially how to start and sequence drugs.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>CKD affects approximately 15% of adults and remains a major cause of kidney failure and cardiovascular events. Several newer drug classes\u2014sodium-glucose cotransporter 2 inhibitors, nonsteroidal mineralocorticoid receptor antagonists, glucagon-like peptide-1 receptor agonists, and endothelin receptor antagonists\u2014provide additional kidney and cardiovascular protection added to standard-of-care renin-angiotensin system inhibition, but the real-world acceptability of using these agents in combination is uncertain. To evaluate the willingness of people with CKD and clinicians to use multidrug combination therapy and to characterize perceived benefits, risks, and barriers to implementation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a cross-sectional, descriptive, semiquantitative online survey of adults with CKD and clinicians who prescribe CKD therapies. Parallel questionnaires captured demographics, current treatment, prior experience with multidrug regimens, willingness to receive or prescribe combination therapy, and ranked priorities and concerns.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>One hundred forty-two people living with CKD and 317 clinicians completed the survey. Most CKD respondents resided in Australia or the United Kingdom; most surveyed clinicians were hospital-based physicians. Willingness to use multiple agents to reduce CKD progression was high (113\/142, 80% \u201cyes\u201d; 27\/142, 19% \u201cmaybe\u201d). Respondents with CKD prioritized reducing CKD progression and preventing complications, while highlighting side effects, long-term safety, and drug-drug interactions as key concerns; pill burden and cost were less frequently prioritized. Clinicians strongly supported combination therapy in a trial context (300\/317, 95%) and reported basing prescribing on guideline recommendations, trial evidence, kidney function, and albuminuria. Principal barriers were risks of hyperkalemia and acute eGFR decline, intensified biochemical monitoring, and cost\/limited access. Most clinicians preferred staggered rather than simultaneous initiation, typically starting with a sodium-glucose cotransporter 2 inhibitor as the first add-on to background renin-angiotensin system inhibitor therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>People with CKD and clinicians support multidrug combination therapy, but concerns regarding safety, monitoring burden, and affordability must be addressed to enable routine implementation and large-scale trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.34067\/kid.0000001227","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T16:02:50Z","timestamp":1780416170000},"page":"1772-1780","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["A Dose of Perspective"],"prefix":"10.34067","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8997-2161","authenticated-orcid":false,"given":"Nasir A.","family":"Shah","sequence":"first","affiliation":[{"name":"The George Institute of Global Health, UNSW Sydney, Sydney, New South Wales, Australia"},{"name":"Faculty of Medicine and Health, School of Clinical Medicine, UNSW Sydney, Sydney, New South Wales, Australia"},{"name":"Department of Nephrology, Prince of Wales Hospital, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7481-7000","authenticated-orcid":false,"given":"Rui","family":"Du","sequence":"additional","affiliation":[{"name":"The George Institute of Global Health, UNSW Sydney, Sydney, New South Wales, Australia"},{"name":"School of Basic Medical Science, Tsinghua Medicine, Tsinghua University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9276-8380","authenticated-orcid":false,"given":"Brendon L.","family":"Neuen","sequence":"additional","affiliation":[{"name":"The George Institute of Global Health, UNSW Sydney, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2438-8401","authenticated-orcid":false,"given":"Adeera","family":"Levin","sequence":"additional","affiliation":[{"name":"Division of Nephrology, University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8015-9470","authenticated-orcid":false,"given":"Vivek","family":"Jha","sequence":"additional","affiliation":[{"name":"The George Institute for Global Health, New Delhi, India"},{"name":"Prasanna School of Public Health, Manipal Academy of Higher Education, Manipal, India"},{"name":"School of Public Health, Imperial College, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3126-3730","authenticated-orcid":false,"given":"Hiddo J.L.","family":"Heerspink","sequence":"additional","affiliation":[{"name":"The George Institute of Global Health, UNSW Sydney, Sydney, New South Wales, Australia"},{"name":"Department Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3294-4087","authenticated-orcid":false,"given":"Sradha S.","family":"Kotwal","sequence":"additional","affiliation":[{"name":"The George Institute of Global Health, UNSW Sydney, Sydney, New South Wales, Australia"},{"name":"Faculty of Medicine and Health, School of Clinical Medicine, UNSW Sydney, Sydney, New South Wales, Australia"},{"name":"Department of Nephrology, Prince of Wales Hospital, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the CAPTIVATE investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,6,2]]},"reference":[{"issue":"7 suppl 2","key":"B1-20261029","doi-asserted-by":"crossref","first-page":"S131","DOI":"10.1097\/01.ASN.0000070152.11927.4A","article-title":"Prevalence of kidney damage in Australian adults: the AusDiab kidney study","volume":"14","author":"Chadban","year":"2003","journal-title":"J Am Soc Nephrol."},{"issue":"8","key":"B2-20261029","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1681\/ASN.2005121273","article-title":"International comparison of the relationship of chronic kidney disease prevalence and ESRD risk","volume":"17","author":"Hallan","year":"2006","journal-title":"J Am Soc Nephrol."},{"issue":"1","key":"B3-20261029","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1053\/ajkd.2003.50007","article-title":"Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey","volume":"41","author":"Coresh","year":"2003","journal-title":"Am J Kidney Dis."},{"issue":"10518","key":"B4-20261029","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/S0140-6736(25)01853-7","article-title":"Global, regional, and national burden of chronic kidney disease in adults, 1990-2023, and its attributable risk factors: a systematic analysis for the global burden of disease study 2023","volume":"406","year":"2025","journal-title":"Lancet."},{"issue":"2","key":"B5-20261029","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"New Engl J Med."},{"issue":"15","key":"B6-20261029","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"New Engl J Med."},{"issue":"24","key":"B7-20261029","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"New Engl J Med."},{"issue":"23","key":"B8-20261029","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"New Engl J Med."},{"issue":"2","key":"B9-20261029","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"New Engl J Med."},{"issue":"10184","key":"B10-20261029","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1016\/S0140-6736(19)30772-X","article-title":"Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial","volume":"393","author":"Heerspink","year":"2019","journal-title":"Lancet."},{"issue":"10417","key":"B11-20261029","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1016\/S0140-6736(23)02302-4","article-title":"Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial","volume":"402","author":"Rovin","year":"2023","journal-title":"Lancet."},{"issue":"24","key":"B12-20261029","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"New Engl J Med."},{"issue":"16","key":"B13-20261029","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in heart failure with mildly reduced or preserved ejection fraction","volume":"391","author":"Solomon","year":"2024","journal-title":"New Engl J Med."},{"issue":"10","key":"B14-20261029","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa2108269","article-title":"Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes","volume":"385","author":"Gerstein","year":"2021","journal-title":"New Engl J Med."},{"issue":"4","key":"B15-20261029","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"New Engl J Med."},{"issue":"10193","key":"B16-20261029","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet."},{"issue":"19","key":"B17-20261029","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"New Engl J Med."},{"issue":"10157","key":"B18-20261029","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","article-title":"Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (harmony outcomes): a double-blind, randomised placebo-controlled trial","volume":"392","author":"Hernandez","year":"2018","journal-title":"Lancet."},{"issue":"22","key":"B19-20261029","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"New Engl J Med."},{"issue":"7","key":"B20-20261029","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"New Engl J Med."},{"issue":"21","key":"B21-20261029","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"New Engl J Med."},{"issue":"15","key":"B22-20261029","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"New Engl J Med."},{"issue":"16","key":"B23-20261029","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"New Engl J Med."},{"issue":"12","key":"B24-20261029","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"New Engl J Med."},{"issue":"24","key":"B25-20261029","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1016\/j.jacc.2025.08.054","article-title":"Pharmacologic treatment of heart failure with reduced ejection fraction: an updated systematic review and network meta-analysis","volume":"86","author":"van Essen","year":"2025","journal-title":"J Am Coll Cardiol."},{"issue":"10305","key":"B26-20261029","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/S0140-6736(21)01922-X","article-title":"Initial treatment with a single pill containing quadruple combination of quarter doses of blood pressure medicines versus standard dose monotherapy in patients with hypertension (QUARTET): a phase 3, randomised, double-blind, active-controlled trial","volume":"398","author":"Chow","year":"2021","journal-title":"Lancet."},{"issue":"10306","key":"B27-20261029","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S0140-6736(21)01827-4","article-title":"Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: an individual participant data meta-analysis","volume":"398","author":"Joseph","year":"2021","journal-title":"Lancet."},{"issue":"2","key":"B28-20261029","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.kint.2020.09.026","article-title":"New insights from SONAR indicate adding sodium glucose co-transporter 2 inhibitors to an endothelin receptor antagonist mitigates fluid retention and enhances albuminuria reduction","volume":"99","author":"Heerspink","year":"2021","journal-title":"Kidney Int."},{"issue":"11","key":"B29-20261029","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1111\/dom.15232","article-title":"Estimated lifetime benefit of novel pharmacological therapies in patients with type 2 diabetes and chronic kidney disease: a joint analysis of randomized controlled clinical trials","volume":"25","author":"Heerspink","year":"2023","journal-title":"Diabetes Obes Metab."},{"issue":"12","key":"B30-20261029","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.2215\/CJN.13601021","article-title":"Atrasentan: the difficult task of integrating endothelin A receptor antagonists into current treatment paradigm for diabetic kidney disease","volume":"16","author":"Ortiz","year":"2021","journal-title":"Clin J Am Soc Nephrol."},{"issue":"8","key":"B31-20261029","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1681\/ASN.2022020207","article-title":"Albuminuria-lowering effect of dapagliflozin, eplerenone, and their combination in patients with chronic kidney disease: a randomized crossover clinical trial","volume":"33","author":"Provenzano","year":"2022","journal-title":"J Am Soc Nephrol."},{"issue":"7","key":"B32-20261029","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s41581-024-00827-z","article-title":"Combination therapy for kidney disease in people with diabetes mellitus","volume":"20","author":"van Raalte","year":"2024","journal-title":"Nat Rev Nephrol."},{"issue":"12","key":"B33-20261029","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.2215\/CJN.07340521","article-title":"The effect of atrasentan on kidney and heart failure outcomes by baseline albuminuria and kidney function: a post hoc analysis of the SONAR randomized trial","volume":"16","author":"Waijer","year":"2021","journal-title":"Clin J Am Soc Nephrol."},{"issue":"6","key":"B34-20261029","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1056\/NEJMoa2410659","article-title":"Finerenone with empagliflozin in chronic kidney disease and type 2 diabetes","volume":"393","author":"Agarwal","year":"2025","journal-title":"New Engl J Med."},{"issue":"10416","key":"B35-20261029","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1016\/S0140-6736(23)02230-4","article-title":"Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial","volume":"402","author":"Heerspink","year":"2023","journal-title":"Lancet."},{"issue":"10518","key":"B36-20261029","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1016\/S0140-6736(25)02014-8","article-title":"Balcinrenone in combination with dapagliflozin compared with dapagliflozin alone in patients with chronic kidney disease and albuminuria: a randomised, active-controlled double-blind, phase 2b clinical trial","volume":"406","author":"Heerspink","year":"2025","journal-title":"Lancet."},{"issue":"4S","key":"B37-20261029","first-page":"S117","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","year":"2024","journal-title":"Kidney Int."},{"issue":"12","key":"B38-20261029","doi-asserted-by":"crossref","first-page":"e2449998","DOI":"10.1001\/jamanetworkopen.2024.49998","article-title":"The global kidney patient trials network and the CAPTIVATE platform clinical trial design: a trial protocol","volume":"7","author":"Kotwal","year":"2024","journal-title":"JAMA Netw Open."},{"issue":"suppl 1","key":"B40-20261029","doi-asserted-by":"crossref","first-page":"i3","DOI":"10.1093\/ndt\/gfae212","article-title":"Combination therapy: an upcoming paradigm to improve kidney and cardiovascular outcomes in chronic kidney disease","volume":"40","author":"Alicic","year":"2025","journal-title":"Nephrol Dial Transplant."},{"issue":"suppl 1","key":"B41-20261029","doi-asserted-by":"crossref","first-page":"i59","DOI":"10.1093\/ndt\/gfae258","article-title":"Combination therapy as a new standard of care in diabetic and non-diabetic chronic kidney disease","volume":"40","author":"Neuen","year":"2025","journal-title":"Nephrol Dial Transplant."},{"issue":"1","key":"B42-20261029","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1681\/ASN.2021070942","article-title":"Hyperkalemia risk with finerenone: results from the FIDELIO-DKD trial","volume":"33","author":"Agarwal","year":"2022","journal-title":"J Am Soc Nephrol."},{"issue":"12","key":"B43-20261029","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1681\/ASN.0000000000000248","article-title":"Effect of SGLT2 inhibitors on discontinuation of renin-angiotensin system blockade: a joint analysis of the CREDENCE and DAPA-CKD trials","volume":"34","author":"Fletcher","year":"2023","journal-title":"J Am Soc Nephrol."},{"issue":"11","key":"B44-20261029","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.jacc.2021.01.044","article-title":"Interplay of mineralocorticoid receptor antagonists and empagliflozin in heart failure: EMPEROR-reduced","volume":"77","author":"Ferreira","year":"2021","journal-title":"J Am Coll Cardiol."},{"issue":"8","key":"B45-20261029","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1016\/j.ekir.2022.05.004","article-title":"Development and external validation of a machine learning model for progression of CKD","volume":"7","author":"Ferguson","year":"2022","journal-title":"Kidney Int Rep."},{"issue":"5","key":"B46-20261029","doi-asserted-by":"crossref","first-page":"sfae098","DOI":"10.1093\/ckj\/sfae098","article-title":"Prediction of incident chronic kidney disease in community-based electronic health records: a systematic review and meta-analysis","volume":"17","author":"Haris","year":"2024","journal-title":"Clin Kidney J."},{"issue":"2","key":"B47-20261029","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1681\/ASN.0000000817","article-title":"Validation of the klinrisk machine learning model for CKD progression in a large representative US population","volume":"37","author":"Tangri","year":"2026","journal-title":"J Am Soc Nephrol."}],"container-title":["Kidney360"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.34067\/KID.0000001227","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T14:01:24Z","timestamp":1793282484000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.34067\/KID.0000001227"}},"subtitle":["A Multinational Survey of Patient and Clinician Views on Combination Therapy in CKD"],"short-title":[],"issued":{"date-parts":[[2026,6,2]]},"references-count":46,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.34067\/kid.0000001227","relation":{},"ISSN":["2641-7650","2641-7650"],"issn-type":[{"value":"2641-7650","type":"electronic"},{"value":"2641-7650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,2]]},"assertion":[{"value":"2026-02-20","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-25","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}